BID and neoplasm: Interestingly, we observed EGF-induced alternative promoter usage of genes that have previously been implicated in tumor progression (e.g., VEGFC, PTK2, IL18 and VAV3) or in cell survival/proliferation (e.g., FBXW7, BID, ABL2) [34], [35].